
    
      This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study
      in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).

      Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be
      compared between HD204 and bevacizumab.
    
  